A Locally Injected Bradykinin Antagonist for TReatment of OSteoarthritiS

NCT01091116 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

423

Enrollment

INDUSTRY

Sponsor class

Conditions

Osteoarthritis, Knee

Interventions

DRUG: MEN16132 - 0.125 mg
DRUG: MEN16132 - 0.25 mg
DRUG: MEN16132 - 0.5 mg
DRUG: MEN16132 - 0.5 mg
DRUG: Placebo

Sponsor

Menarini Group